Enzyme Replacement Therapy Medicines

Concepts

• edinburgh
• pharmaceutical products
• enzyme replacement therapy medicines
• therapy medicines
• therapy
• enzyme
• replacement
• medicines
• fabrazyme®
• cerezyme®

Location

All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014

Description

Supply of Enzyme Replacement Therapy Medicines (a-d) to NHS Scotland: - NP92624(a) Laronidase 500units/5ml solution for infusion vials 1 vial (Aldurazyme®) - NP92624(b) Imiglucerase 400unit powder for solution for infusion vials 1 vial (Cerezyme®) - NP92624(c) Agalsidase beta 35mg powder for solution for infusion vials 1 vial (Fabrazyme®) - NP92624(c) Agalsidase beta 5mg powder for solution for infusion vials 1 vial (Fabrazyme®) - NP92624(d) Alglucosidase alfa 50mg powder for solution for infusion vials 1 vial (Myozyme®)

Total Quantity or Scope

The Framework Agreement is for the supply of Enzyme Replacement Therapy Medicines (a-d: Aldurazyme®/ Cerezyme®/ Fabrazyme®/ Fabrazyme®/ Myozyme®) to NHS Scotland. The Authority has awarded this framework as a Single supplier framework agreement to one (1) Framework Participant.

Award Detail

Award Criteria

CPV Codes

• 33600000 - Pharmaceutical products

Legal Justification

The medicine to be awarded to the framework agreement is protected by exclusive rights, including intellectual property rights, in line with Regulation 33(1)(b)(iii) of the Public Contracts (Scotland) Regulations 2015.

Other Information

** PREVIEW NOTICE, please check Find a Tender for full details. ** The estimated value(s) of the Framework Agreement referred to in Sections II.1.7 and V.2.4 cover(s) the twenty-four (24) month contract duration and the twelve (12) month extension period of the Framework Agreement. (SC Ref:774962)